| 董佳丽,程 贞,李姝君,等.非小细胞肺癌表皮生长因子受体-酪氨酸激酶抑制剂靶向治疗研究进展[J].肿瘤学杂志,2024,30(6):510-517. |
| 非小细胞肺癌表皮生长因子受体-酪氨酸激酶抑制剂靶向治疗研究进展 |
| Research Progress on EGFR-TKI Targeted Therapy for Non-Small Cell Lung Cancer |
| 投稿时间：2023-09-29 |
| DOI：10.11735/j.issn.1671-170X.2024.06.B010 |
|
 |
| 中文关键词: 癌，非小细胞肺 表皮生长因子受体－酪氨酸激酶抑制剂 耐药 全程管理 靶向治疗 新辅助治疗 辅助治疗 |
| 英文关键词:cancer, non-small cell lung epidermal growth factor receptor-tyrosine kinase inhibitors drug resistance mechanism whole-process management targeted therapy neoadjuvant therapy adjuvant therapy |
| 基金项目: |
|
| 摘要点击次数: 112 |
| 全文下载次数: 55 |
| 中文摘要: |
| 摘 要：以表皮生长因子受体-酪氨酸激酶抑制剂（epidermal growth factor receptor-tyrosine kinase inhibitors ，EGFR-TKIs）为代表的靶向治疗药物已显著改善非小细胞肺癌(non-small cell lung cancer，NSCLC)患者的预后。随着肿瘤全程管理的推进，不断有研究展开探讨EGFR-TKIs在新辅助治疗、辅助治疗及晚期一线治疗（EGFR-TKIs单药治疗和联合化疗、抗血管生成治疗及免疫治疗）中的疗效。而EGFR-TKIs耐药成为靶向治疗无法避免的问题，导致耐药后的治疗陷入瓶颈。全文就EGFR-TKIs的临床应用、耐药机制及抗耐药治疗进行综述。 |
| 英文摘要: |
| Abstract： Targeted therapy represented by epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) has significantly improved the prognosis of patients with non-small cell lung cancer (NSCLC). The efficacy of EGFR-TKIs (including EGFR-TKIs monotherapy and combined with chemotherapy， anti-angiogenesis therapy and immunotherapy) in neoadjuvant therapy， adjuvant therapy and first-line treatment for advanced-stage patients has been extensively explored. However， resistance to EGFR-TKIs in targeted therapy has become a challenge leading to the difficulty in post-resistance treatment. This paper reviews the clinical application， resistance mechanisms and anti-resistance treatments of EGFR-TKIs. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |